Clinical Insights: Role of Ropeginterferon Alfa-2b-njft in Polycythemia Vera
Key Points
-
Traditional polycythemia vera (PV) therapies, including aspirin, phlebotomy, and hydroxyurea, remain important for blood count and thrombosis control but have limited long-term disease-modifying effects.
-
Hydroxyurea is effective for many patients, although long-term use may be associated with toxicities, reduced efficacy, and challenges maintaining disease control.
-
Ropeginterferon alfa-2b-njft has shown durable hematologic responses and improved long-term outcomes compared with hydroxyurea, making it an increasingly preferred frontline option for many patients with PV.
-
Experts emphasized the role of interferon therapy in long-term disease modification, including reducing progression risk and, in some cases, achieving treatment-free remission, while continuing to monitor for manageable adverse effects.
Oncology Brothers podcast co-hosts Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, were joined by Aaron Gerds, MD, of Cleveland Clinic; Anthony Hunter, MD, of Winship Cancer Institute of Emory University; and Anand Patel, MD, of the University of Chicago, for a Clinical Insights discussion on evolving treatment approaches in PV. During the discussion, which coincided with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the panel focused on traditional therapies, the expanding role of ropeginterferon, and the increasing emphasis on long-term disease modification.
The discussion opened with a review of long-standing PV therapies, including aspirin and phlebotomy. Dr. Gerds emphasized how deeply rooted these interventions are in medical history while questioning whether they are sufficient for modern disease management. “It’d be nice to move forward 3000 years in the way we treat patients with PV,” he said.
Although studies such as ECLAP and CYTO-PV established the value of aspirin use and maintaining hematocrit levels below 45%, panelists agreed these strategies primarily address short-term thrombotic risk rather than altering the natural history of the disease.
Hydroxyurea remains a commonly used cytoreductive therapy and provides meaningful benefit for many patients, particularly older individuals seeking an oral treatment option. Dr. Patel noted that dose flexibility allows clinicians to individualize therapy, but long-term management can become challenging as disease biology evolves. Adverse effects such as nausea, taste changes, ulcerations, and nonmelanoma skin cancers may complicate treatment over time, while maintaining durable blood count control can become increasingly difficult in some patients.
Ropeginterferon Alfa-2b-njft and Long-Term Disease Modification
The conversation then shifted toward ropeginterferon, which panelists described as a major advance in PV treatment. Dr. Hunter reviewed the development program leading to approval, including the PROUD-PV and CONTINUATION-PV studies. These trials compared ropeginterferon with hydroxyurea and demonstrated noninferiority in hematologic control during early treatment periods, followed by superior long-term outcomes with continued follow-up.
Importantly, panelists emphasized that ropeginterferon’s value may extend beyond hematocrit management. Dr. Gerds highlighted the growing focus on disease modification, noting that deeper molecular responses may translate into improved long-term outcomes. “We’re not looking for the next 2, 3 years just to simply reduce clot risk,” he said. “That’s your short-term goal, but 10, 20, 30 years down the road, how can we prevent progression of myelofibrosis or maybe even progression to acute leukemia?”
Dr. Patel added that younger patients represent a particularly important population for considering interferon-based therapy. He cited retrospective European data demonstrating impressive myelofibrosis-free survival among adolescents and young adults treated with interferons. For many clinicians, the possibility of altering disease trajectory over decades has become central to treatment discussions, particularly for patients with a long anticipated life expectancy.
Tolerability, Monitoring, and Treatment Sequencing
Historically, concerns surrounding interferon toxicity limited enthusiasm for widespread use. However, panelists agreed that ropeginterferon offers a substantially improved tolerability profile compared with earlier nonpegylated interferons.
Dr. Hunter explained that extended dosing intervals and steadier drug exposure have significantly reduced the flu-like symptoms traditionally associated with interferon therapy. Dr. Gerds added that age alone should not exclude patients from treatment consideration.
Another major topic involved monitoring JAK2 variant allele frequency (VAF) during treatment. Although clinicians increasingly recognize the prognostic significance of molecular responses, opinions differed regarding routine testing in clinical practice.
Interferon therapy can substantially reduce allele burden over time, occasionally leading to undetectable disease levels and treatment-free remissions in select patients, Dr. Gerds explained. “I have some patients in my clinic who are now 5 years with normal blood counts and no treatment,” he said. “It’s a pretty remarkable phenomenon.”
Dr. Patel cautioned that routine VAF testing may not meaningfully change management for many patients whose blood counts remain stable. Instead, he said, he reserves testing primarily for situations in which treatment discontinuation is being considered.
Dr. Hunter noted that he uses JAK2 monitoring more liberally in patients receiving ropeg, particularly when evaluating potential treatment holidays or sustained molecular responses.
Continued Evolution of Sequencing Strategies
The panel concluded with a discussion surrounding treatment sequencing and future therapeutic integration. Dr. Gerds noted that current NCCN Guidelines position ropeginterferon as the preferred frontline cytoreductive therapy for low-risk patients requiring treatment. Emerging therapies such as rusfertide may further refine treatment algorithms in coming years.
Dr. Patel described rusfertide primarily as an adjunctive strategy designed to reduce phlebotomy requirements rather than directly modify disease biology or reduce allele burden. As additional long-term data become available, clinicians anticipate continued evolution in how these therapies are sequenced and combined.